ப்ராடக்ட் வளர்ச்சி ஆராய்ச்சி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Dialectic Therapeutics Receives FDA Clearance of IND Application for Lead Antiapoptotic Protein Targeted Degradation (APTaD) Candidate DT2216 News provided by Share this article DALLAS, March 3, 2021 /PRNewswire/  Dialectic Therapeutics, Inc. (Dialectic ®), a Texas-based biotechnology company focused on creating innovative new technologies to treat cancer, today announced that the U.S. Food and Drug Administration (FDA) has concluded that Dialectic may proceed with its clinical investigation for its lead product candidate, DT2216, a unique compound built using its proprietary and novel Antiapoptotic Targeted Degradation (APTaD™) technology. In pre-clinical studies supported through a Seed Award from the Cancer Prevention & Research Institute of Texas (CPRIT), DT2216 selectively induces cancer cells to degrade B-cell lymphoma extra-large, or BCL-XL, stimulating the cells to commit suicide or become more susceptible to chemotherapy.

United statesJohnd harkey jrRobert hromasDavid genecovJosh sillsSeed award for product development researchUniversity of florida healthDialectic therapeutics incUt health san antonioDrug administrationCancer prevention research institute of texasDean of the long school medicineDialectic therapeuticsSeed awardCancer preventionResearch institute